DSDavid S. Schrump

David S. Schrump

*This is an algorithmically generated author record based on publicly available information.

David S. Schrump has a total of 340 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

    by Haobin Chen, Lisa Gesumaria, Young-Kwon Park, Trudy G. Oliver, Dinah S. Singer, Kai Ge, David S. Schrump

    Small-cell lung cancer (SCLC) is a recalcitrant malignancy that urgently needs new therapies. Four master transcription factors (ASCL1, NEUROD1, POU2F3, and YAP1) have been identified in SCLC, and each defines the transcriptome landscape of one molecular subtype. However, these master transcription factors have not been found directly druggable. We hypothesized that blocking their transcriptional coactivator(s) could provide an alternative approach to target these master transcription factors. Here, we identify that BET proteins physically interact with NEUROD1 and function as transcriptional coactivators. Using CRISPR knockout and ChIP-seq, we demonstrate that NEUROD1 plays a critical role in defining the landscapes of BET proteins in the SCLC genome. Blocking BET proteins by inhibitors led to broad suppression of the NEUROD1-target genes, especially those associated with superenhancers, resulting in the inhibition of SCLC growth in vitro and in vivo. LSAMP, a membrane protein in the IgLON family, was identified as one of the NEUROD1-target genes mediating BET inhibitor sensitivity in SCLC. Altogether, our study reveals that BET proteins are essential in regulating NEUROD1 transactivation and are promising targets in SCLC-N subtype tumors.Implications:Our findings suggest that targeting transcriptional coactivators could be a novel approach to blocking the master transcription factors in SCLC for therapeutic purposes.

  • Open Access

    Supplementary tables 5-17 - Data tables generated during RNA-seq and ChIP-seq analysis, and the information on the siRNA screens. from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

    by Haobin Chen, Lisa Gesumaria, Young-Kwon Park, Trudy G. Oliver, Dinah S. Singer, Kai Ge, David S. Schrump

    Table S5. The list of genes significantly altered in H446 cells after NEUROD1 KO. Table S6. The list of NEUROD1 peaks identified in H446 control cells (control gRNA, cl.10) Table S7. The list of NEUROD1 target genes identified by BETA. Table S8. Gene Descriptions Table S9. The list of genomic regions singly occupied by BRD4 in H446 control cells (control gRNA cl. 10). Table S10. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 control cells (control gRNA cl.10). Table S11. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 NEUROD1-KO cells (#297 cl.2-1). Table S12. The list of genes with significantly altered expression after JQ1 treatment (24 hours at 0.5µM) in COR-L279 cells. Table S13. The list of NEUROD1-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S14. The list of BRD4-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S15. The list of BRD4-loaded superenhancers in H446 NEUROD1-KO cells (#297 cl.2-1). Table S16. Information on the Qiagen custom siRNA library. Table S17. The list of genes with significantly altered expression in SCLC PDX LX22 following 5-day NHWD-870 treatment (3mg/kg via gavage daily; n=6 /group).

  • Open Access

    Supplemental methods, supplemental tables 1-4, and supplemental figures 1-14 from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

    by Haobin Chen, Lisa Gesumaria, Young-Kwon Park, Trudy G. Oliver, Dinah S. Singer, Kai Ge, David S. Schrump

    Table S1. The list of the SCLC cell lines (N=52) used in this study. Table S2. The list of 384 genes that constitute the NEUROD1 gene signature. Table S3. The siRNA screen results in H446 and COR-L279 cells. Table S4. Sensitivity (IC50) of SCLC lines (N=52) to JQ1 and NHWD-870. Figure S1. Knockout of NEUROD1 by CRISPR in H446 cells. Figure S2. Validation of the H446 NEUROD1 ChIP-seq. Figure S3. BET bromodomain proteins interact with NEUROD1 in H524 cells. Figure S4. BRD4 interacts with ASCL1 in H1963 cells. Figure S5. NEUROD1 KO affects the BRD4 occupancy only in the genomic regions co-occupied by NEUROD1. Figure S6. Neuronal-related pathways are enriched among the NEUROD1-target genes in H446 cells. Figure S7. Validation of the NEUROD1 gene signature using the SCLC RNA-seq dataset in the CCLE. Figure S8. Effects of BETi on NEUROD1 gene expression in H446 cells. Figure S9. The NEUROD1- and BRD4-loaded SEs identified in H446 control and NEUROD1-KO cells and their correlation. Figure S10. The SCLC-N lines are more susceptible to BETi. Figure S11. NEUROD1 KO renders DMS-273 cells resistant to BETi. Figure S12. Effects of NEUROD1 KO on MYC expression and transactivation. Figure S13. LSAMP expression is regulated by both NEUROD1 and BET bromodomain proteins. Figure S14. Correlation between the IC50 values of NHWD-870 and JQ1 in SCLC cell lines (N=28)

  • Open Access

    Prospective Analysis of Mesotheliomas in Subjects With BAP1 Cancer Syndrome: Clinical Characteristics and Epigenetic Correlates of Disease

    by Xinwei Wu, Frank Villa Hernandez, Haitao Wang, Ruihong Wang, Stephanie Shiffka, Niharika Shah, Shamus R. Carr, Chuong D. Hoang, Andrew M. Blakely, Alexandra Lebensohn, et al.


  • Open Access

    Repression of ZNFX1 by LncRNA ZFAS1 mediates tobacco-induced pulmonary carcinogenesis

    by Sichuan Xi, Jigui Shan, Xinwei Wu, Haitao Wang, Mary R. Zhang, Shakirat Oyetunji, Hong Xu, Zuoxiang Xiao, Tuana Tolunay, Shamus R. Carr, et al.

    Background: Despite exhaustive research efforts, integrated genetic and epigenetic mechanisms contributing to tobacco-induced initiation and progression of lung cancers have yet to be fully elucidated. In particular, limited information is available regarding dysregulation of noncoding RNAs during pulmonary carcinogenesis. Methods: We examined correlations and interactions of long noncoding (lnc) RNAs and protein-coding genes in normal respiratory epithelial cells (NREC) and pulmonary tumor cells following exposure to cigarette smoke condensate (CSC) using gene expression arrays, qRT-PCR, western blot, growth assays, transwell assays, and murine xenograft models, as well as methylated DNA immunoprecipitation, RNA cross-link immunoprecipitation, and quantitative chromatin immunoprecipitation techniques with bioinformatics analyses. Results: Among diverse alterations of lncRNA and coding gene expression profiles in NREC exposed to CSC, we observed upregulation of lncRNA ZFAS1 and repression of an adjacent protein-coding gene, ZNFX1, and confirmed these findings in primary lung cancers. Phenotypic experiments indicated that ZFAS1 is an oncogene, whereas ZNFX1 functions as a tumor suppressor in lung cancer cells. Mechanistically, CSC induces ZFAS1 expression via SP1 and NFĸB-associated activation of an enhancer linked to ZFAS1. Subsequently, ZFAS1 interacts with DNA methyltransferases and polycomb group proteins to silence ZNFX1. Mithramycin and methysticin repress ZFAS1 and upregulate ZNFX1 in lung cancer cells in vitro and in vivo. Conclusion: These studies reveal a novel feedforward lncRNA circuit contributing to pulmonary carcinogenesis and suggest that pharmacologic targeting of SP1 and/or NFĸB may be useful strategies for restoring ZNFX1 expression for lung tumor therapy.


  • Genome-Wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in SCLC

    by Vivek Shukla, Haitao Wang, Lyuba Varticovski, Songjoon Baek, Ruihong Wang, Xinwei Wu, Frank Echtenkamp, Frank Villa-Hernandez, Katherine P. Prothro, Sudheer K. Gara, et al.


  • Open Access

    CPADS: a web tool for comprehensive pancancer analysis of drug sensitivity

    by Kexin Li, Hong Yang, Anqi Lin, Jiayi Xie, Haitao Wang, Jianguo Zhou, Shamus R Carr, Zaoqu Liu, Xiaohua Li, Jian Zhang, et al.

    Drug therapy is vital in cancer treatment. Accurate analysis of drug sensitivity for specific cancers can guide healthcare professionals in prescribing drugs, leading to improved patient survival and quality of life. However, there is a lack of web-based tools that offer comprehensive visualization and analysis of pancancer drug sensitivity. We gathered cancer drug sensitivity data from publicly available databases (GEO, TCGA and GDSC) and developed a web tool called Comprehensive Pancancer Analysis of Drug Sensitivity (CPADS) using Shiny. CPADS currently includes transcriptomic data from over 29 000 samples, encompassing 44 types of cancer, 288 drugs and more than 9000 gene perturbations. It allows easy execution of various analyses related to cancer drug sensitivity. With its large sample size and diverse drug range, CPADS offers a range of analysis methods, such as differential gene expression, gene correlation, pathway analysis, drug analysis and gene perturbation analysis. Additionally, it provides several visualization approaches. CPADS significantly aids physicians and researchers in exploring primary and secondary drug resistance at both gene and pathway levels. The integration of drug resistance and gene perturbation data also presents novel perspectives for identifying pivotal genes influencing drug resistance. Access CPADS at https://smuonco.shinyapps.io/CPADS/ or https://robinl-lab.com/CPADS.


  • Open Access

    Data from Inhibition of Histone Lysine Methylation Enhances Cancer–Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer

    by Mahadev Rao, Nachimuthu Chinnasamy, Julie A. Hong, Yuwei Zhang, Mary Zhang, Sichuan Xi, Fang Liu, Victor E. Marquez, Richard A. Morgan, David S. Schrump

    Cancer–testis antigens (CTA), such as NY-ESO-1, MAGE-A1, and MAGE-A3, are immunogenic proteins encoded by genes, which are normally expressed only in male germ cells but are activated by ill-defined epigenetic mechanisms in human tumors, including lung cancers. Previously, we reported induction of these CTAs in cancer cells, but not normal cells, by DNA-demethylating agents and histone deacetylase inhibitors using clinically achievable exposure conditions. In the present study, we evaluated chromatin alterations associated with repression/activation of cancer–testis genes in lung cancer cells to further develop gene-induction regimens for cancer immunotherapy. Repression of NY-ESO-1, MAGE-A1, and MAGE-A3 coincided with DNA hypermethylation, recruitment, and binding of polycomb-group proteins, and histone heterochromatin modifications within the promoters of these genes. Derepression coincided with DNA demethylation, dissociation of polycomb proteins, and presence of euchromatin marks within the respective promoters. Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression. Knockdown of KMT6, KDM1, or KDM5B markedly enhanced deoxyazacytidine (DAC)-mediated activation of these cancer–testis genes in lung cancer cells. DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown. Following DAC–DZNep exposure, lung cancer cells were specifically recognized and lysed by allogeneic lymphocytes expressing recombinant T-cell receptors recognizing NY-ESO-1 and MAGE-A3. Combining DNA-demethylating agents with compounds, such as DZNep, that modulate histone lysine methylation may provide a novel epigenetic strategy to augment cancer–testis gene expression as an adjunct to adoptive cancer immunotherapy. Cancer Res; 71(12); 4192–204. ©2011 AACR.

  • Open Access

    mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer

    by Anju Kumari, Lisa Gesumaria, Yan-Jin Liu, V. Keith Hughitt, Xiaohu Zhang, Michele Ceribelli, Kelli M. Wilson, Carleen Klumpp-Thomas, Lu Chen, Crystal McKnight, et al.

    Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited treatment options. Bromodomain and extraterminal domain inhibitors (BETis) have shown promising preclinical activity in SCLC, but the broad sensitivity spectrum limits their clinical prospects. Here, we performed unbiased high-throughput drug combination screens to identify therapeutics that could augment the antitumor activities of BETis in SCLC. We found that multiple drugs targeting the PI-3K–AKT–mTOR pathway synergize with BETis, among which mTOR inhibitors (mTORis) show the highest synergy. Using various molecular subtypes of the xenograft models derived from patients with SCLC, we confirmed that mTOR inhibition potentiates the antitumor activities of BETis in vivo without substantially increasing toxicity. Furthermore, BETis induce apoptosis in both in vitro and in vivo SCLC models, and this antitumor effect is further amplified by combining mTOR inhibition. Mechanistically, BETis induce apoptosis in SCLC by activating the intrinsic apoptotic pathway. However, BET inhibition leads to RSK3 upregulation, which promotes survival by activating the TSC2-mTOR-p70S6K1-BAD cascade. mTORis block this protective signaling and augment the apoptosis induced by BET inhibition. Our findings reveal a critical role of RSK3 induction in tumor survival upon BET inhibition and warrant further evaluation of the combination of mTORis and BETis in patients with SCLC.